NRF2 activates several protective genes, such as sulfiredoxin (SRXN1), as a response to oxidative and xenobiotic stress. Defects in NRF2 pathway may increase cancer susceptibility. In tumor cells activation of NRF2 may lead to chemo-and radioresistance and thus affect patient outcome. Nine single nucleotide polymorphisms (SNPs) on NRF2 gene and eight on SRXN1 were genotyped in 452 breast cancer patients and 370 controls.
INTRODUCTION
Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcriptional factor which senses oxidative and xenobiotic stress in the cells (1) . When such stress occurs, NRF2 is released from a complex formed with KEAP1 (Kelch-like ECH-associated protein 1), a substrate adaptor of a Cullin 3-based E3 ubiquitin ligase complex, and moves to the nucleus where it associates with maf proteins and then upregulates several stress related genes such as glutathione-S-transferases, thioredoxin, thioredoxin reductases, peroxiredoxins, gamma glutamyl cysteine ligase, heme oxygenase 1, NADPH kinone oxidoreductase and multidrug resistance genes (1, 2) . If NRF2 stays in a complex with KEAP1 in cytoplasm, it is degraded through the proteasome pathway (1, 2) .
The function of NRF2 is important in the pathogenesis of several diseases. Mice with a non-functioning Nrf2 gene develop early onset emphysema because of a deficient antioxidative response (3) . Similarly mice lacking Nrf2 develop nutritional steatohepatitis (4) . A high amount of unbound NRF2 in cancer cells results in chemoresistance of the tumor cells (5) . The importance of NRF2 and KEAP1 in tumorigenesis is underlined by the fact that tumor cells may contain mutations in the respective genes. NRF2 mutations are present in oesophageal, skin, larynx and lung cancer with a 6-13 % frequency with the highest prevalence in squamous cell carcinomas (6) . A similar mutational frequency has been found for KEAP1 with an incidence of 15 % in lung cancer (7) . Loss of KEAP1 function leads to increased NRF2 concentration and chemoresistancy in non-small cell lung cancer (8) . In addition to somatic mutations, genomic low penetrance DNA variations could have an effect to the function of these genes and their downstream targets. Author Manuscript Published OnlineFirst on September 10, 2012; DOI: 10.1158/0008-5472. CAN-12-1474 Peroxiredoxins are enzymes, which have capability in scavenging hydrogen peroxide and other peroxides (9, 10) . Peroxiredoxins may undergo reversible oxidation in their cysteine sites to sulfinic acid rendering the molecules to degradation (10, 11) . Sulfiredoxin catalyses the reversal of overoxidation of peroxiredoxins, thus salvaging them from inactivation (11) . Sulfiredoxin is also involved in deglutathionylation of proteins following nitrosactive or oxidative stress (12) . In cell lines, overexpression of sulfiredoxin has been shown to stimulate cell proliferation and apoptosis induced by cisplatin, the effects of which were mediated by phosphorylation of cell cycle regulators and kinases (13) .
Sulfiredoxin is induced by NRF2 and AP-1 and protects the lung from tobacco mediated oxidative damage (14, 15) . Increased sulfiredoxin has been linked with oncogenic transformation, and it is overexpressed in various skin cancers (16) .
There are many risk factors associated with the development of breast carcinoma, and 1-5 % of them have a hereditary basis (17) . Even though oxidative damage is considered as one mechanism for cancer development, its role in breast cancer has not been extensively studied. Since NRF2 is known to be a sensor of oxidative damage, we studied its expression in different types of breast carcinoma. Additionally we investigated the expression and significance of sulfiredoxin, a known target for NRF2, in breast carcinoma.
MATERIALS AND METHODS

DNA samples
DNA from 452 patients with invasive breast cancer and 370 control subjects from the Kuopio Breast Cancer Project (KBCP) sample set were available for genotyping (Supplemental Table S1 ). The KBCP sample set consists of 497 prospective breast cancer cases and 458 controls from the province of Northern Savo in Eastern Finland. The KBCP sample material is characterized in more detail by Hartikainen et al. 2005 (18) and Pellikainen et al. 2003 (19) . Genomic DNA was extracted from peripheral blood lymphocytes of both cases and controls using standard procedures (20) . The KBCP has been approved by the ethical committee of University of Eastern Finland and Kuopio University Hospital.
Tumor material in tissue microarray
The tumor material consisted of 373 cases of invasive breast carcinomas included in the KBCP. The clinical characteristics of the material are shown in Supplemental Table S1 .
Paraffin-embedded tumor tissue from the primary tumor was obtained from breast cancer surgery. Tissue microarray was constructed as previously described (21) .
Single nucleotide polymorphism (SNP) selection
Tagging single nucleotide polymorphism (tagSNPs) for NRF2 and SRXN1 genes were selected using the HapMap Genome Browser release 2 (Phase 3, NCBI build 36, bdSNP (23, 24) . (Supplemental Figure   S1A and B)
Genotyping of NRF2 and SRXN1 SNPs The results for NRF2 were semiquantitated as follows; 0-5 %=negative, over 5 to 25 %= weak positivity, over 25 to 75 %=moderate positivity, over 75 to 100 %= strong positivity.
In the analyses, NRF2 expression was divided in two groups, low extent (< 25 %) and high extent (> 25 %) expression. For sulfiredoxin the presence (> 1 %) or absence of cytoplasmic expression was recorded.
Statistical analysis
The statistical analyses were performed with SPSS for Windows software v 14.0 (SPSS, Chicago, IL,USA). Continuous data were compared using analysis of variance (ANOVA).
When ANOVA results indicated that groups differed, post hoc comparisons were performed using two-tailed t-tests. Categorical data were compared using Fisher's exact test designed for small sample groups. 
RESULTS
NRF2
rs6721961 and rs2706110 associate with increased risk of breast cancer and SRXN1 rs6053666 protects against breast cancer Seven tagging SNPs (rs1806649, rs2886162, rs1962142, rs2364722, rs10183914, rs2706110 and rs13035806) and two functional SNPs (rs6721961 and rs6706649) were analysed in the NRF2 gene region. Eight tagging SNPs (rs6085283, rs13043781, rs6076869, rs6053666, rs2008022, rs6116929, rs7269823 and rs6053728) were analyzed in the SRXN1 gene region (Supplemental Table S2 ). The SNP genotypes were tested for concordance with the Hardy-Weinberg equilibrium (HWE). Among the controls NRF2 rs6706649 deviated slightly from HWE with a P value of 0.029. All other genotypes were concordant with the HWE.
Among the invasive breast cancer cases an association with breast cancer risk was observed with NRF2 rs6721961 and rs2706110, and SRXN1 rs6053666 genotypes ( Table   1) . The rare homozygous genotypes of NRF2 rs6721961 (TT) and rs2706110 (AA) associated with increased risk of breast cancer, whereas the common allele was protective (Table 1) . The rare allele C of SRXN1 rs6053666 was protective (Table 1) . A near significant association was observed with NRF2 rs13035806 (Table 1) .
NRF2 expression associates with sulfiredoxin expression
High extent (> 25 %) cytoplasmic NRF2 positivity was seen in 66 % (237/361) and nuclear Table S3 ).
NRF2 SNP rare alleles associate with low extent cytoplasmic NRF2 and sulfiredoxin protein expression A significant association was observed with cytoplasmic NRF2 protein expression and the NRF2 rs1962142, rs2886162 and rs6721961 genotypes among the invasive breast cancer cases, the rare alleles associating with low extent cytoplasmic NRF2 protein expression (Table 2) . The rare alleles of NRF2 rs1962142 and rs6721961 also associated with negative sulfiredoxin protein expression (Table 2 ). More specifically, NRF2 rs6721961 rare allele associated with grade 2 tumors (P (Overall) =0.041, P (Allele specific) =0.012, OR=1.975, CI=1.159-3.365) and NRF2 rs2886162 rare homozygous genotype AA associated with ER positive breast cancer (P (Overall) =0.008, P (Allele specific) =0.008, OR=2.518, CI=1.276-4.969).
NRF2 SNP rs1962142 allele T also associated with grade 2 tumors (data not shown). This SNP resides in the same haplotype block with rs6721961 and most likely represents the same association as rs6721961. (Table 2 ) and with lobular histology (P (Overall) =0.019, P (Allele specific) =0.022, OR=1.830, CI=1.092-3.066).
NRF2 and SRXN1 genotypes associate with prognosis/survival NRF2 rs2886162 rare homozygous genotype AA associated with a worse survival compared to the carriers of the common allele G (Kaplan-Meier P (log rank) =0.017, Supplemental Table S4 , Supplemental Figure S2 ). This association remained significant in the multivariate analysis (Cox regression P=0.032, HR=1.687, CI=1.047-2.748, Table 3, Figure 2 ). In this multivariate analysis also the cytoplasmic NRF2 expression was included but it did not associate with survival. However, in the Kaplan-Meier analysis a difference in the genotype-associated survival was observed between the strata (cytoplasmic NRF2 low extent vs. high extent, P=0.023, log rank 5.163), implying that the genotypes association is most significant among those with low extent cytoplasmic NRF2 only (Supplemental Table   S5 , Supplemental Figure S3A and B). Similar trend was observed with nuclear NRF2 protein expression (P=0.019, log rank 5.490) (Supplemental Table S5 , Supplemental Figure S4A and B).
SRXN1 rs6116929 rare homozygous genotype GG and rs2008022 rare allele carriers CA&AA had better survival compared to the common allele (P (log rank) =0.063 and P (log Research. Figure S5A and B). SRXN1 rs7269823 and rs6085283 rare allele carriers (AG&GG and CT&TT, respectively) had poorer survival compared to the common homozygous genotype (P (log rank) =0.030 and P (log rank) =0.015, respectively, Supplemental Table S4 , Supplemental Figure S5C and D). In the Cox regression analysis including all four survival-associated SRXN1 polymorphisms only rs2008022 remained significant (P=0.012, HR=1.645, CI=1.116-2.425). None of these four polymorphisms however, were independently significant prognostic factors in the multivariate analysis including tumor grade, nodal status, ER status, PR status, histological type, tumor size and HER2 status (Cox regression, data not shown).
Effect of combined NRF2 and SRXN1 genotypes on prognosis/survival
We further studied the effect of the combined SRXN1 survival-associated polymorphisms by summing up the number of the risk alleles of the SRXN1 polymorphisms rs61169295, rs2008022, rs7269823 and rs6085283 for each patient. The highest value possible was 8 and the lowest was zero. The patients were divided in two groups; 0-3 risk alleles and 4-8 risk alleles. A trend towards poorer survival was observed with increasing amount of risk alleles in Kaplan-Meier analysis (P (log rank) =0.009 for 0-3 vs. 4-8 risk alleles, Supplemental Figure S6 ). However, the poorest survival was still defined by rs2008022. When the effect of NRF2 rs2886162 was also considered together with the combined SRXN1 SNPs there was a difference in the survival between the strata defined by rs2886162 genotype (P=0.014, log rank 6.009). Among the rs2886162 rare allele (A) carriers poorer survival was observed among those with 4-8 SRXN1 risk alleles(P (log rank) =0.010) but no difference among the rs2886162 common homozygotes (GG) was observed (P (log rank) =0.638) (Supplemental Figure S7A and Table S6 , Supplemental Figure S8A ). Similar results were obtained from the multivariate analysis including the clinicopathological variables, NRF2 protein expression (cytoplasmic and nuclear), sulfiredoxin protein expression, combined SRXN1 genotypes and rs2886162 (Supplemental Table S7 , Supplemental Figure S8B ).
NRF2 rs2886162 AA genotype independently predicts poorer survival among patients who received chemotherapy or radiation therapy
The effect of NRF2 rs2886162 rare homozygous genotype AA on poor prognosis was also seen separately in the group that had received adjuvant chemotherapy (CT) and among those that received postoperative radiation therapy (RT). In the group that had received adjuvant CT the rs2886162 genotype AA associated with poorer breast cancer survival 
SRXN1 genotypes independently predict survival among patients receiving radiation treatment
The effect of the SRXN1 genotypes on prognosis also holds when radiation treatment is taken into account. SRXN1 rs6116929 rare homozygous genotype GG and rs2008022 rare allele carriers CA&AA predicted better prognosis among the patients who received RT (Supplemental Table S8 , Figure 4A and B). Also, among the patients treated with RT, the SRXN1 rs7269823 and rs6085283 rare allele carriers (AG&GG and CT&TT, respectively) had poorer survival compared to the patients carrying the common homozygous genotypes (Supplemental Table S8 , Figure 4C and D). In addition, among the patients treated with RT the SRXN1 rs6053666 rare homozygous genotype CC predicted better prognosis compared to the common allele carriers (Supplemental Table S8 ). Interestingly, rs6053666 rare allele also associates with decreased breast cancer risk. Our results demonstrate that in the NRF2 pathway there are genetic polymorphisms that affect both the susceptibility for breast cancer and the outcome of the breast cancer patients, thus underlining the complex effect of NRF2 in cancer progression. On one hand, the NRF2 promoter polymorphism rs6721961 associates with breast cancer risk referring to the role of NRF2 in cancer predisposition. The rare allele T associates with increased risk of breast cancer and low protein level of both NRF2 and sulfiredoxin. The T allele is predicted to destroy a binding site for a transcription factor (intronic enhancer) c-Rel (FastSNP, ref. 28) (Supplemental Table S9 ). Previously, rs6721961 has been shown to be functional (24) and hence it would directly affect the protein expression level of NRF2.
Indeed, here we have demonstrated the connection between the T allele and decreased NRF2 protein expression in breast cancer tissue, as well as the resulting decrease in sulfiredoxin expression. This is also concordant with the hypothesis that impaired NRF2 function leads to decreased sulfiredoxin function, which in turn affects the function of peroxiredoxins and leads to increased cancer proneness. Decreased NRF2 level and HO-1 did not have any significance for the risk of breast cancer (30) . When the risk polymorphisms of these genes were combined, patients with three risk alleles had a 1.5 fold risk and those with a high iron intake had a greater than 2 fold risk (30) . In postmenopausal women with oral estrogen replacement therapy the NRF2 rs6721961 rare allele seems to modify the risk of thromboembolism (31) . NRF2 polymorphism has, however, been more extensively studied in pulmonary disease (24, 32, 33) . While NRF2 polymorphisms clearly may promote individuals for oxidative damage, no published studies on their significance in lung cancer exist. Lung cancer, as well known, is associated with tobacco smoke which among other effects provokes development of ROS (34) . Polymorphisms rs6721961 and rs6706649 have been studied in gastric carcinogenesis but no overall association with risk was found (35) . In gastric cancer, carcinogenesis is predominantly based on H. pylori induced gastritis leading to gastric atrophy and cancer, while in breast cancer hormonal factors play a role (36) . It is known that estrogen metabolites induce the formation of reactive oxygen species (37) . In this sense NRF2 and its dysfunction may be more important in breast carcinogenesis than gastric cancer.
In addition to NRF2 polymorphisms, we observed that polymorphisms on SRXN1 also are Table S9 ). It is possible that these polymorphisms affect the level or function of sulfiredoxin and the cancer cells exhibiting low sulfiredoxin expression have lower tolerance for oxidative damage and the response for oxidative damage is poor, which promotes/enhances the death of the cancer cell and a better response to treatment and thus, leads to better outcome. The effect of sulfiredoxin in breast carcinoma could be connected to its role in converting peroxiredoxins to a functional, reduced state. Some peroxiredoxins have been associated with progression of breast cancer. Overexpression of peroxiredoxin VI in breast carcinoma cell lines leads to a more invasive phenotype with a higher proliferative activity (40) . Moreover, peroxiredoxin III promotes breast cancer cell proliferation and peroxiredoxins I, II and III protect cells from oxidative damage induced apoptosis (41, 42) . We also found that SRXN1 rs6053666 CAN-12-1474 region of the SRXN1 gene and is predicted to participate in splicing regulation (alternative splicing). Three exonic splicing enhancer (ESE) binding sites are predicted for allele C (SF2/ASF, SC35 and SRp55), and none for allele T (FastSNP, F-SNP) (Supplemental Table S9 ). 
